Measuring Quality of Life in Hidradenitis Suppurativa: Development and Validation of a Disease-specific Patient-reported Outcome Measure for Practice and Research
DOI:
https://doi.org/10.2340/actadv.v102.2485Keywords:
quality of life, burden, well-being, patient-reported outcome measure, validation, validation, hidradenitis suppurativaAbstract
Hidradenitis suppurativa is a chronic disease that disrupts patients’ physical and psychological well-being. A disease-specific measure was developed and validated for assessing health-related quality of life in hidradenitis suppurativa. After qualitative item development, the quality of life in hidradenitis suppurativa instrument was tested in 101 patients, applying convergent measures and a usability questionnaire. Descriptive and validation-specific analyses were conducted. There was no ceiling, but moderate floor effects (scores between 0 and 3.13 on a scale of 0–4). Few missing values were observed (21 of 23 items < 5%). Internal consistency was satisfying: 2 subscales with 6 and 16 items were identified (Cronbach’s alpha=0.95 and 0.88). The quality of life in hidradenitis suppurativa instrument correlated significantly with all convergent criteria (including change in convergent patient-reported outcomes; p < 0.05) except for Hurley stage (p = 0.490). In conclusion, the quality of life in hidradenitis suppurativa questionnaire is an internally consistent, valid, responsive, and usable instrument to assess quality of life in patients with hidradenitis suppurativa.
Downloads
References
Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 2017; 318: 2019-2032.
https://doi.org/10.1001/jama.2017.16691 DOI: https://doi.org/10.1001/jama.2017.16691
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2020; 82: 1045-1058.
https://doi.org/10.1016/j.jaad.2019.08.090 DOI: https://doi.org/10.1016/j.jaad.2019.08.090
Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol 2017; 10: 105-115.
https://doi.org/10.2147/CCID.S111019 DOI: https://doi.org/10.2147/CCID.S111019
Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GBE. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 2015; 231: 184-190.
https://doi.org/10.1159/000431175 DOI: https://doi.org/10.1159/000431175
Esmann S, Jemec GBE. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol 2011; 91: 328-332.
https://doi.org/10.2340/00015555-1082 DOI: https://doi.org/10.2340/00015555-1082
Jfri A, Nassim D, O'Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol 2021; 157: 924-931.
https://doi.org/10.1001/jamadermatol.2021.1677 DOI: https://doi.org/10.1001/jamadermatol.2021.1677
Cosmatos I, Matcho A, Weinstein R, Montgomery MO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 2013; 69: 819.
https://doi.org/10.1016/j.jaad.2013.06.042 DOI: https://doi.org/10.1016/j.jaad.2013.06.042
Theut Riis P, Pedersen OB, Sigsgaard V, Erikstrup C, Paarup HM, Nielsen KR, et al. Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study. Br J Dermatol 2019; 180: 774-781.
https://doi.org/10.1111/bjd.16998 DOI: https://doi.org/10.1111/bjd.16998
Kirsten N, Petersen J, Hagenström K, Augustin M. Epidemiology of hidradenitis suppurativa in Germany - an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol 2020; 34: 174-179.
https://doi.org/10.1111/jdv.15940 DOI: https://doi.org/10.1111/jdv.15940
Kirsten N, Zander N, Augustin M. Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Arch Dermatol Res 2021; 313: 95-99.
https://doi.org/10.1007/s00403-020-02065-2 DOI: https://doi.org/10.1007/s00403-020-02065-2
Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191-194.
https://doi.org/10.1016/S0190-9622(96)90321-7 DOI: https://doi.org/10.1016/S0190-9622(96)90321-7
Vekic DA, Frew JW, Woods J, Cains GD. Adopting the orphan: the importance of recognising hidradenitis suppurativa as a systemic auto-inflammatory disease. Australas J Dermatol 2016; 57: 69-70.
https://doi.org/10.1111/ajd.12287 DOI: https://doi.org/10.1111/ajd.12287
Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol 2020; 183: 999-1010.
https://doi.org/10.1111/bjd.19556 DOI: https://doi.org/10.1111/bjd.19556
Nikolakis G, Kokolakis G, Kaleta K, Wolk K, Hunger R, Sabat R, et al. Pathogenese der hidradenitis suppurativa/acne inversa. Hautarzt 2021; 72: 658-665.
https://doi.org/10.1007/s00105-021-04853-x DOI: https://doi.org/10.1007/s00105-021-04853-x
Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2015; 29: 371-376.
https://doi.org/10.1111/jdv.12567 DOI: https://doi.org/10.1111/jdv.12567
Mavrogiorgou P, Juckel G, Reimelt A, Hessam S, Scholl L, Frajkur JL, et al. Psychiatrische Komorbidität bei Hidradenitis suppurativa/Acne inversa. Hautarzt 2021; 72: 426-434.
https://doi.org/10.1007/s00105-020-04742-9 DOI: https://doi.org/10.1007/s00105-020-04742-9
Balieva F, Kupfer J, Lien L, Gieler U, Finlay AY, Tomás-Aragonés L, et al. The burden of common skin diseases assessed with the EQ5D™: a European multicentre study in 13 countries. Br J Dermatol 2017; 176: 1170-1178.
https://doi.org/10.1111/bjd.15280 DOI: https://doi.org/10.1111/bjd.15280
Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-623.
https://doi.org/10.1016/j.jaad.2006.08.061 DOI: https://doi.org/10.1016/j.jaad.2006.08.061
Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010; 90: 264-268.
https://doi.org/10.2340/00015555-0866 DOI: https://doi.org/10.2340/00015555-0866
Chernyshov PV, Finlay AY, Tomas-Aragones L, Poot F, Sampogna F, Marron SE, et al. Quality of life in hidradenitis suppurativa: an update. Int J Environ Res Public Health 2021; 18.
https://doi.org/10.3390/ijerph18116131 DOI: https://doi.org/10.3390/ijerph18116131
Zouboulis CC, Chernyshov PV. Hidradenitis suppurativa-specific, patient-reported outcome measures. J Eur Acad Dermatol Venereol 2021; 35: 1420-1421.
https://doi.org/10.1111/jdv.17306 DOI: https://doi.org/10.1111/jdv.17306
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Pinard J, Vleugels RA, Joyce C, Merola JF, Patel M. Hidradenitis suppurativa burden of disease tool: Pilot testing of a disease-specific quality of life questionnaire. J Am Acad Dermatol 2018; 78: 215-217.e2.
https://doi.org/10.1016/j.jaad.2017.08.030 DOI: https://doi.org/10.1016/j.jaad.2017.08.030
Thorlacius L, Esmann S, Miller I, Vinding G, Jemec GBE. Development of HiSQOL: a hidradenitis suppurativa-specific quality of life instrument. Skin Appendage Disord 2019; 5: 221-229.
https://doi.org/10.1159/000496234 DOI: https://doi.org/10.1159/000496234
Kimball AB, Sundaram M, Banderas B, Foley C, Shields AL. Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa. J Dermatolog Treat 2018; 29: 152-164.
https://doi.org/10.1080/09546634.2017.1341614 DOI: https://doi.org/10.1080/09546634.2017.1341614
Sisic M, Kirby JS, Boyal S, Plant L, McLellan C, Tan J. Development of a quality-of-life measure for hidradenitis suppurativa. J Cutan Med Surg 2017; 21: 152-155.
https://doi.org/10.1177/1203475416677721 DOI: https://doi.org/10.1177/1203475416677721
McLellan C, Sisic M, Oon HH, Tan J. Preliminary validation of the HS-QoL: a quality-of-life measure for hidradenitis suppurativa. J Cutan Med Surg 2018; 22: 142-146.
https://doi.org/10.1177/1203475417736281 DOI: https://doi.org/10.1177/1203475417736281
Marrón SE, Gómez-Barrera M, Tomás-Aragonés L, Díaz Díaz RM, Vilarrasa Rull E, Madrid Álvarez MB, et al. Desarrollo y validación preliminar del instrumento HSQoL-24 para evaluar calidad de vida en pacientes con hidradenitis supurativa. Actas Dermosifiliogr (Engl Ed) 2019; 110: 554-560.
https://doi.org/10.1016/j.ad.2019.02.002 DOI: https://doi.org/10.1016/j.ad.2019.02.002
Chiricozzi A, Bettoli V, Pità O de, Dini V, Fabbrocini G, Monfrecola G, et al. HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2019; 33: e24-e26.
https://doi.org/10.1111/jdv.15122 DOI: https://doi.org/10.1111/jdv.15122
Chernyshov PV, Zouboulis CC, Tomas-Aragones L, Jemec GB, Svensson A, Manolache L, et al. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol 2019; 33: 1633-1643.
https://doi.org/10.1111/jdv.15519 DOI: https://doi.org/10.1111/jdv.15519
Thorlacius L, Ingram JR, Villumsen B, Esmann S, Kirby JS, Gottlieb AB, et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol 2018; 179: 642-650.
https://doi.org/10.1111/bjd.16672 DOI: https://doi.org/10.1111/bjd.16672
Finlay AY, Salek MS, Abeni D, Tomás-Aragonés L, van Cranenburgh OD, Evers AWM, et al. Why quality of life measurement is important in dermatology clinical practice: an expert-based opinion statement by the EADV Task Force on Quality of Life. J Eur Acad Dermatol Venereol 2017; 31: 424-431.
https://doi.org/10.1111/jdv.13985 DOI: https://doi.org/10.1111/jdv.13985
Augustin M, Amon U, Braathen L, Bullinger M, Gieler U, Klein GF, et al. Erfassung von Lebensqualität in der Dermatologie. J Dtsch Dermatol Ges 2004; 2: 802-806.
https://doi.org/10.1046/j.1439-0353.2004.04505.x DOI: https://doi.org/10.1046/j.1439-0353.2004.04505.x
Aaronson N, Alonso J, Burnam A, Lohr KN, Patrick DL, Perrin E, et al. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002; 11: 193-205.
https://doi.org/10.1023/A:1015291021312 DOI: https://doi.org/10.1023/A:1015291021312
Mokkink LB, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, Vet HCW de, et al. COSMIN study design checklist for patient-reported outcome measurement instruments; 2019.
Blome C, Augustin M, Heyer K, Knöfel J, Cornelsen H, Purwins S, et al. Evaluation of patient-relevant outcomes of lymphedema and lipoedema treatment: development and validation of a new benefit tool. Eur J Vasc Endovasc Surg 2014; 47: 100-107.
https://doi.org/10.1016/j.ejvs.2013.10.009 DOI: https://doi.org/10.1016/j.ejvs.2013.10.009
Mayring P. Qualitative content analysis: a step-by-step guide / Philipp Mayring. 1st. Los Angeles: SAGE; 2021.
EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
https://doi.org/10.1016/0168-8510(90)90421-9 DOI: https://doi.org/10.1016/0168-8510(90)90421-9
Freedman D, Pisani R, Purves R. Statistics. International student edn, 4th edn / David Freedman, Robert Pisani, Roger Purves. New York: W.W. Norton & Co.; 2007.
Eremenco S, Pease S, Mann S, Berry P. Patient-Reported Outcome (PRO) Consortium translation process: consensus development of updated best practices. J Patient Rep Outcomes 2017; 2: 12.
https://doi.org/10.1186/s41687-018-0037-6 DOI: https://doi.org/10.1186/s41687-018-0037-6
Schäfer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010; 20: 62-67.
https://doi.org/10.1684/ejd.2010.0815 DOI: https://doi.org/10.1684/ejd.2010.0815
Kirby JS, Thorlacius L, Villumsen B, Ingram JR, Garg A, Christensen KB, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol 2020; 183: 340-348.
https://doi.org/10.1111/bjd.18692 DOI: https://doi.org/10.1111/bjd.18692
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Marina Otten, Matthias Augustin, Christine Blome, Janine Topp, Marina Niklaus, Caroline Hilbring, Falk G. Bechara, Andreas Pinter, Christos C. Zouboulis, Florian Anzengruber, Natalia Kirsten
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
